HCPCS Q0238 is officially defined as "Injection, tocilizumab-aazg, for hospitalized adult patients with covid-19 who are receiving systemic corticosteroids and require supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo) only, 1 mg." HCPCS Q0238 is referenced in 9 tracked payer policy changes from Blue Cross Blue Shield of Rhode Island, BCBS Michigan, and 4 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS Q0238 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Blue Cross Blue Shield of Rhode Island updated HCPCS Level II code coverage and payment rules effective April 1, 2026. Multiple codes have new coverage designations including newly covered codes, non-covered codes, medical review requirements, and pharmacy benefit changes.
Blue Cross Blue Shield of Michigan has implemented its Q1 2026 HCPCS code updates, adding 56 new codes and deleting 6 codes effective April 1, 2026. Most new skin substitute codes (A2040-A2045, Q4418-Q4440) are not covered, while new drug/injection codes (J-codes) and COVID-19 related codes are generally covered.
Texas Medicaid is implementing first quarter 2026 HCPCS updates effective April 1, 2026, adding new covered and non-covered procedure codes with specific age limitations and prior authorization requirements. Several existing codes are being discontinued with direct replacements required.
Texas Medicaid CSHCN Services Program is implementing Q1 2026 HCPCS updates effective April 1, 2026. Multiple codes are being added as benefits (pending rate hearings), added as non-covered, or discontinued entirely. Several new codes require prior authorization and have age restrictions.
Kansas Medicaid (KMAP) is adding 13 new HCPCS codes for coverage and discontinuing 6 existing codes effective April 1, 2026. Billing teams must update their systems to use the new codes and stop billing the discontinued ones.
Independence Blue Cross Medicare Advantage updated policy MA08.045p to MA08.045r, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar COVID-19 treatment in hospitalized patients. The policy clarifies preferred versus nonpreferred tocilizumab products, establishes coverage criteria for multiple indications including rheumatoid arthritis and Castleman disease, and specifies that biosimilars require documented contraindication, intolerance, or inadequate response to preferred products before coverage of nonpreferred alternatives.
Independence Blue Cross updated policy 08.00.85s to version 08.00.85u, adding three new HCPCS codes (M0233, M0234, Q0238) for tocilizumab-aazg biosimilar infusions in hospitalized COVID-19 patients. The policy designates tocilizumab-aazg (Tyenne) and tocilizumab-anoh (Avtozma IV) as preferred products, with nonpreferred products requiring prior documentation of contraindication, intolerance, or inadequate response to preferred options.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes added in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. Codes marked noncovered are not covered for any IHCP program. Pricing for the new codes depends on CMS fee schedules that were still awaiting final posting, and claims submitted before pricing is entered into the claim-processing system may initially be denied.
The Indiana Health Coverage Programs (IHCP) set coverage and billing information for procedure codes in the April 2026 quarterly HCPCS update, effective for dates of service on or after April 1, 2026. This bulletin replaces the originally published update in IHCP Bulletin BT202649, and it sets prior authorization criteria for J3404, J9183, and the Q5161 and Q5162 biosimilars. Codes discontinued effective March 31, 2026 have no alternative codes identified by the IHCP, and codes marked allowed for podiatrists (provider specialty 140) are limited to that provider specialty.
Watch Q0238
Get one email when a payer policy names Q0238, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for Q0238
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for Q0238 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.